C.R. Bard to license hernia repair product from Genzyme
Dec 17 (Reuters) - Medical-device maker C.R. Bard Inc (BCR.N: Quotazione) said it entered into a license deal with biotech firm Genzyme Corp GENZ.O to make and market the Sepramesh hernia repair product line and incorporate a related coating technology into future hernia repair applications.
A unit of Bard will begin marketing the line immediately, the company said in a statement. Details of the agreement were not disclosed. (Reporting by Avishek Mishra in Bangalore; Editing by Pratish Narayanan)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.